date:Aug 25, 2016
ved as scientific consultants for tobacco companies, which of course have a long history denying and manipulating scientific findings. Other researchers analyzing the makeup of GRAS expert panels have found a similar trend.
The Government Accountability Office (GAO) recommended in a 2010 report that the FDA develop a strategy to minimize the potential for conflicts of interest in companies GRAS determinations. How did the FDA respond to these concerns in its final rule? Well, the FDA plans to i